首页> 外文期刊>Bioanalysis >Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver
【24h】

Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver

机译:同时测定大鼠肝脏帕利他韦和利托那韦的UPLC-MS / MS方法的开发和验证

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: Determination of paritaprevir and ritonavir in rat liver tissue samples. Results: We successfully validated a UPLC-MS/MS method to measure paritaprevir and ritonavir in rat liver using deuterated internal standards (d8-paritapervir and d6-ritonavir). The method is linear from 20 to 20,000 and 5 to 10,000 pg on column for paritaprevir and ritonavir, respectively, and is normalized per milligram tissue. Interday and intraday variability ranged from 0.591 to 5.33% and accuracy ranged from -6.68 to 10.1% for quality control samples. The method was then applied to the measurement of paritaprevir and ritonavir in rat liver tissue samples from a pilot study. Conclusion: The validated method is suitable for measurement of paritaprevir and ritonavir within rat liver tissue samples for PK studies.
机译:目的:测定大鼠肝脏组织样品中的帕利他普韦和利托那韦。结果:我们成功地验证了使用氘化内标(d8-paritapervir和d6-ritonavir)在大鼠肝脏中测量paritaprevir和ritonavir的UPLC-MS / MS方法。对于paritaprevir和ritonavir,该方法的色谱柱线性分别为20至20,000 pg和5至10,000 pg,并且每毫克组织标准化。对于质量控制样品,日间和日内差异在0.591%至5.33%之间,准确度在-6.68%至10.1%之间。然后将该方法用于一项前瞻性研究在大鼠肝脏组织样品中帕瑞他韦和利托那韦的测量。结论:经验证的方法适用于大鼠肝脏组织样品中帕瑞他韦和利托那韦的测定,用于PK研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号